Winelands Medical Research Centre | Stellenbosch, South Africa

Research site

(Unclaimed)

Location

c/o Saffraan & Rokewood Ave, Stellenbosch, Western Cape, South Africa

Site insights

Top conditions

Top treatments

Upadacitinib

Adalimumab

LY3009104

Baricitinib

Filgotinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 6 total trials

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting

Psoriatic Arthritis

Biological: Placebo

Biological: Risankizumab

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting

Psoriatic Arthritis (PsA)

Biological: Placebo

Biological: Risankizumab

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis (OLINGUITO)

This study is comparing 200 milligrams (mg) of filgotinib a day with a placebo to see if filgotinib helps to treat Axial Spondyloarthritis (axSpA) an...

Active, not recruiting

Axial Spondyloarthritis

Drug: Placebo

Drug: Filgotinib

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA-BRIDGE)

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Active, not recruiting

Rheumatoid Arthritis

Drug: Baricitinib

Drug: TNF Inhibitor

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling

Systemic Lupus Erythematosus

Drug: Upadacitinib

Drug: Placebo

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH)

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how...

Enrolling

Rheumatoid Arthritis

Drug: Adalimumab

Drug: Upadacitinib

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms